In parallel, ginsenoside Rg1 decreased the level of Aβ1-42 by upregulating the expressions of PPARγ and insulin-degrading enzyme in hippocampus of a rat model of AD, demonstrating ginsenoside Rg1 has potential as a therapeutic agent for AD treatment (Quan et al., 2013). Here, PPARG is linked to Alzheimer disease.